Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B

CÜRE, Ekan; ŞAHİN KIR, Figen; ÇİÇEK ÇOPUR, Ayşegül; PARLAK, Emine; CÜRE CUMHUR, Medine; ERTÜRK, AYŞE

Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B

Ayşe ERTÜRK, (Recep Tayyip Erdoğan Üniversitesi, Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları Kliniği, Rize, Türkiye)

Ekan CÜRE, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Rize, Türkiye)

Emine PARLAK, (Atatürk Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları Anabilim Dalı, Erzurum, Türkiye)

Medine CÜRE CUMHUR, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Biyokimya Ana Bilim Dalı, Rize, Türkiye)

Ayşegül ÇİÇEK ÇOPUR, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Rize, Türkiye)

Figen ŞAHİN KIR (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, Rize, Türkiye)

Viral Hepatitis Journal

1 0

Yıl: 2014 Cilt: 20 Sayı: 1 Sayfa Aralığı: 23 - 27 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B

Öz:

Amaç: Perinatal geçiş, hepatit B virüs (HBV) hastalığının en sık bulaşma yollarındanbiridir. Bu geçişi önlemek, bebeğe uygulanan pasif ve aktif immünizasyona ekolarak yüksek viral yükü olan gebeye uygulanan antiviral tedaviler ile mümkündür.Gebelik sırasında antiviral tedavinin güvenilirliğini ve gebe ile çocukta Hepatit Bserokonversiyonu üzerine etkilerini araştırmayı amaçladık. Gereç ve Yöntemler: Kronik hepatit B (KHB)li viral yükü yüksek gebelerden 2011- 2013 yılları arasında hastanemiz enfeksiyon hastalıkları polikliniğine başvuran 17hastaya uygulanan antiviral tedavilerin (lamivudin, telbivudin, tenofovir) anne veçocuk üzerindeki sonuçları retrospektif olarak değerlendirildi. Bulgular: KHBli gebelerde HBV-DNA seviyelerinin 8-12 haftalık antiviral tedaviyitakiben 11/17 (%64,7) hastada ≤10 000 IU/mL seviyelerine gerilediği ortalama>2log10 (IU/mL) azalma olduğu, hastaların 15/17 (%88,2)sinde karaciğerenzimlerinin gerilediği, anne ve çocukta ilaç yan etki ve komplikasyonlarınıngelişmediği gözlendi. Sonuç: HBsAgsi pozitif gebelerde antiviral tedavi sonrası viral yük azalmakta,perinatal geçiş engellenmekte, bu sayede sadece immunizasyon ile HBVserokonversiyonu elde etme amacı desteklenmektedir.

Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji

Kronik Hepatit B li Gebelerde Uygulanan Antiviral Tedavi Sonuçlarının Değerlendirilmesi

Öz:

Objective: Perinatal transmission is one of the most common transmission routesof hepatitis B virus (HBV) disease. It is possible to prevent transmission withantiviral treatment performed in pregnant women with high viral load in adition tothe passive and active immunization treatment performed in the infant. The aim ofthis study was to investigate the safety of antiviral treatment during pregnancy andits effects on the seroconvertion of Hepatitis B in pregnant and newborn. Materials and Methods: The effects of antiviral treatment (lamivudine, tenofovir,telbivudine) performed in 17 pregnant women who were admitted to the infectiousdisease outpatient clinic of our hospital between years 2011-2013 and who hadchronic hepatitis B (CHB) and a high viral load on the mother andt the newborn wereevaluated retrospectively.Results: Following 8-12 weeks of antiviral treatment, HBV-DNA levels weredecreased to ≤10.000 IU/mL in the 11/17 (64.7%) patients, there were >2log10(IU / mL) of reduction in average, liver enzymes were decreased in 15/17 (88.2%)patients. There were no observed drug side effects and complications in motherand newborn. Conclusion: After the antiviral therapy viral load decreased in HBsAg positivepregnant women and perinatal transmission is prevented, thus, this supported theaim of obtaining HBV seroconversion only with immunization .

Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Tran TT. Management of hepatitis B in pregnancy: Weighing the options. cleveland clin J Med. 2009; 76(suppl 3): 25-29.
2. Köse Ş, Türken M, Devrim İ, Taner c. efficacy and safety of lamivudine treatment in late pregnancy with high HBV DnA: a perspective for mother and infants. J Infect Dev ctries. 2011; 5: 303-306.
3. Bzowej nH. Optimal Management of the hepatitis B patient who desires pregnancy or is pregnant. curr Hepatitis rep. 2012; 11: 82-89.
4. natalie H. Bzowej. Hepatitis B therapy in pregnancy. curr Hepatitis rep. 2010; 9: 197-204.
5. World Health Organization. Hepatitis B. World Health Organization fact sheet n°204 updated July 2013. Available at http://www.who.int/mediacentre/factsheets/fs204/en/
6. Al-naamani K, Al-Maqbali A, Al-sinani s. characteristics of hepatitis B infection in a sample of Omani patients. sultan Qaboos univ Med J. 2013; 13: 380-385.
7. ergunay K, Balaban Y, cosgun e, Alp A, simsek H, sener B, Tatar G, Hascelik G. Ann epidemiologic trends in HBV infections at a reference centre in Turkey: an 11-year retrospective analysis. Ann Hepatol. 2012; 11: 672-678.
8. Karlıdağ Ge. elazığ kent merkezinde Bir hastaneye başvuran gebelerde HBsAg seroprevalansı. Fü sağ Bil Tıp Derg. 2011; 25: 111-113.
9. çiçek Aç, Duygu F, İnakçı İH. Şanlıurfa ilinde Kadın Hastalıkları ve Doğum Hastanesine başvuran kadınlarda hepatit B ve hepatit c seroprevalansı: üç yıllık değerlendirme. Viral Hepatit Dergisi. 2012; 18: 15-18.
10. Balık G, ü Işık, Kağıtcı M. rize bölgesinde yaşayan gebe kadınlarda HBsAg, antiHBs ve anti-HcV seroprevalansı. Dicle Tıp Dergisi. 2013; 40: 254-257.
11. chen HL1, Lin LH, Hu Fc, Lee JT, Lin WT, Yang YJ, Huang Fc, Wu sF, chen sc, Wen WH, chu cH, ni YH, Hsu HY, Tsai PL, chiang cL, shyu MK, Lee PI, chang FY, chang MH. effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012; 142: 773-781.
12. chang KM. Hepatitis B immunology for clinicians. clin Liver Dis. 2010; 14: 409-424.
13. centers for Disease control and Prevention. Disease burden from hepatitis A, B and c; 2011. Available at:http://www.cdc. gov/hepatitis/statistics/index.htm.
14. nayeri uA, Werner eF, Han cs, Pettker cM, Funai eF, Thung sF. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. Am J Obstet Gynecol. 2012; 207: 231.e1-7.
15. Pan cQ1, Mi LJ, Bunchorntavakul c, Karsdon J, Huang WM, singhvi G, Ghany MG, reddy Kr. Ttenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus ınfection by highly viremic pregnant women: a case series. Dig Dis sci. 2012; 57: 2423-2429.
16. Xu XW and chen YG. current therapy with nucleoside/ nucleotide analogs for patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2006; 5: 350-359.
17. Xu WM, cui YT, Wang L, Yang H, Liang zQ, Li XM, zhang sL, Qiao FY, campbell F, chang cn, Gardner s, Atkins M. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009; 16: 94-103.
18. Lee, nM, Brady c W. Liver disease in pregnancy. World J Gastroenterol. 2009; 15: 897-906.
19. european Association For The study Of The Liver. eAsL clinical Practice Guidelines:Management of chronic hepatitis B. J Hepatol. 2009; 50: 227-242.
20. Han Gr1, cao MK, zhao W, Jiang HX, Wang cM, Bai sF, Yue X, Wang GJ, Tang X, Fang zX. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011; 55: 1215-1221.
21. Han L, zhang HW, Xie JX, zhang Q, Wang HY, cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol. 2011; 17: 4321-4333.
22. van zonneveld M, van nunen AB, niesters HG, de Man rA, schalm sW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003; 10: 294-297.
23. Liu M, cai H, Yi W. safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat. 2013; 20(suppl 1): 65-70.
24. Pan cQ1, Han Gr, Jiang HX, zhao W, cao MK, Wang cM, Yue X, Wang GJ. Telbivudine prevents vertical transmission from HBeAg-Positive women with chronic hepatitis B. clin Gastroenterol Hepatol. 2012; 10: 520-526.
25. ter Borg MJ, Leemans WF, de Man rA, Janssen HL. exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008; 15: 37-41.

APA	ERTÜRK A, CÜRE E, PARLAK E, CÜRE CUMHUR M, ÇİÇEK ÇOPUR A, ŞAHİN KIR F (2014). Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. , 23 - 27.
Chicago	ERTÜRK AYŞE,CÜRE Ekan,PARLAK Emine,CÜRE CUMHUR Medine,ÇİÇEK ÇOPUR Ayşegül,ŞAHİN KIR Figen Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. (2014): 23 - 27.
MLA	ERTÜRK AYŞE,CÜRE Ekan,PARLAK Emine,CÜRE CUMHUR Medine,ÇİÇEK ÇOPUR Ayşegül,ŞAHİN KIR Figen Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. , 2014, ss.23 - 27.
AMA	ERTÜRK A,CÜRE E,PARLAK E,CÜRE CUMHUR M,ÇİÇEK ÇOPUR A,ŞAHİN KIR F Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. . 2014; 23 - 27.
Vancouver	ERTÜRK A,CÜRE E,PARLAK E,CÜRE CUMHUR M,ÇİÇEK ÇOPUR A,ŞAHİN KIR F Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. . 2014; 23 - 27.
IEEE	ERTÜRK A,CÜRE E,PARLAK E,CÜRE CUMHUR M,ÇİÇEK ÇOPUR A,ŞAHİN KIR F "Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B." , ss.23 - 27, 2014.
ISNAD	ERTÜRK, AYŞE vd. "Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B". (2014), 23-27.

APA	ERTÜRK A, CÜRE E, PARLAK E, CÜRE CUMHUR M, ÇİÇEK ÇOPUR A, ŞAHİN KIR F (2014). Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. Viral Hepatitis Journal, 20(1), 23 - 27.
Chicago	ERTÜRK AYŞE,CÜRE Ekan,PARLAK Emine,CÜRE CUMHUR Medine,ÇİÇEK ÇOPUR Ayşegül,ŞAHİN KIR Figen Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. Viral Hepatitis Journal 20, no.1 (2014): 23 - 27.
MLA	ERTÜRK AYŞE,CÜRE Ekan,PARLAK Emine,CÜRE CUMHUR Medine,ÇİÇEK ÇOPUR Ayşegül,ŞAHİN KIR Figen Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. Viral Hepatitis Journal, vol.20, no.1, 2014, ss.23 - 27.
AMA	ERTÜRK A,CÜRE E,PARLAK E,CÜRE CUMHUR M,ÇİÇEK ÇOPUR A,ŞAHİN KIR F Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. Viral Hepatitis Journal. 2014; 20(1): 23 - 27.
Vancouver	ERTÜRK A,CÜRE E,PARLAK E,CÜRE CUMHUR M,ÇİÇEK ÇOPUR A,ŞAHİN KIR F Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. Viral Hepatitis Journal. 2014; 20(1): 23 - 27.
IEEE	ERTÜRK A,CÜRE E,PARLAK E,CÜRE CUMHUR M,ÇİÇEK ÇOPUR A,ŞAHİN KIR F "Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B." Viral Hepatitis Journal, 20, ss.23 - 27, 2014.
ISNAD	ERTÜRK, AYŞE vd. "Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B". Viral Hepatitis Journal 20/1 (2014), 23-27.